RLM.L Regulatory News (RLM)

27 Mar 2007 13:54

PuriCore (LSE:PURI), the life sciences company focused on thedevelopment and commercialisation of its novel, safe antimicrobialtechnology, today announces that its Sterilox Endoscopy division hasestablished a sales and marketing partnership with BHT HygienetechnikGmbH, the Frost and Sullivan award winning manufacturer of endoscopereprocessors and channel checking systems (INNOVA(R) CC). £ This new partnership significantly enhances PuriCore's productportfolio. The combination of Frost and Sullivan award-winningtechnologies from Sterilox Endoscopy and BHT will deliver amongst thefastest and safest large pass through reprocessing systems in the UK.The deal ensures that PuriCore and BHT can respond to their clients'need for high quality infection control. £ This joint approach is proving successful, and a number of ordershave already been confirmed and reprocessing systems are due to beinstalled over the coming months. £ This deal follows last month's announcement that PuriCore hadsigned an exclusive distribution agreement with Minntech Corporation,one of the world's leading manufacturers of automated endoscopereprocessors. £ "PuriCore is pleased to announce another partnership with aworld-class AER manufacturer," said Greg Bosch, chief executiveofficer of PuriCore. "The integration of our technologies providessignificant cost-saving benefits to our NHS customers and furtherstrengthens our position as the UK's leading provider of endoscopyreprocessing systems." £ "The joint effort allows BHT to expand its existing offerings inthe UK market for high level disinfection solutions in the mostsensitive field of reprocessing flexible endoscopes," said Dr.Annecke, CEO and managing director of BHT. £ About PuriCore £ PuriCore (LSE:PURI) is a life sciences company focused on thedevelopment and commercialization of its proprietary technology thatmimics the production by the human body of its natural anti-microbial,hypochlorous acid. Hypochlorous acid is highly effective at killingpathogens such as bacteria, viruses and fungi and yet is safe andenvironmentally friendly. PuriCore's solutions have applications in awide range of markets where it is important to control microbialcontamination. These markets include medical device disinfection, foodsafety, dental equipment decontamination, environmental remediation,hospitality, water safety, wound management and other applicationsintended to limit the spread of infectious disease, including majorglobal disease threats such as Tuberculosis, MRSA, Influenza, E.coli,Norovirus, HIV, polio, Hepatitis A, H.pylori and Legionella. £ PuriCore markets a portfolio of branded systems which producehypochlorous acid solutions on-site at a customer's location fromwater, electricity and common salt. These solutions are generated at arange of concentrations and at a nearly neutral pH range similar tothe human body. They are effective as soaks, sprays, mists and inother forms. £ PuriCore is headquartered in Malvern, Pennsylvania with offices inStafford, UK. £ To receive additional information on PuriCore or its SteriloxEndoscopy division, please visit our web site at www.puricore.com,which does not form part of this press release. £ About BHT £ BHT is one of the acknowledged market leaders in the design andmanufacturing of innovative washers and disinfectors for the medical,dental, laboratory and pharmaceutical market for more than 25 years.BHT distributes products and service to domestic and internationalclients from its world wide headquarter in Gersthofen near Augsburg,Germany. The company has been awarded in 2005 with the Frost &Sullivan Product Innovation Award, Healthcare for its INNOVA CCproduct. BHT is certified according DIN EN ISO 9001 and DIN EN 13485. Copyright Business Wire 2007